

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**Form 8-K**

**CURRENT REPORT**

Pursuant to Section 13 OR 15(d)  
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 11, 2023

**Amgen Inc.**

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

001-37702  
(Commission  
File Number)

95-3540776  
(IRS Employer  
Identification No.)

One Amgen Center Drive  
Thousand Oaks  
California  
(Address of principal executive offices)

91320-1799  
(Zip Code)

Registrant's telephone number, including area code:  
(805) 447-1000

Not Applicable  
(Former Name or Former Address, if Changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered under Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value	AMGN	The Nasdaq Stock Market LLC
2.000% Senior Notes Due 2026	AMGN26	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

**Item 8.01      Other Events**

As previously disclosed, Amgen Inc. (“Amgen”), Pillartree Limited, a private limited company incorporated under the laws of Ireland and a wholly owned subsidiary of Amgen, and Horizon Therapeutics plc (“Horizon”) entered into that certain Transaction Agreement (the “Transaction Agreement”), dated as of December 11, 2022. On September 11, 2023, Amgen and Horizon jointly acknowledged that the First Extended End Date (as defined in the Transaction Agreement) has been automatically extended to the Second Extended End Date (i.e., December 12, 2023).

As also previously disclosed, on September 5, 2023, the Irish High Court set a court hearing for October 5, 2023 to consider Horizon’s application for sanction of the scheme of arrangement under Irish law.

*Responsibility Statement Required by the Irish Takeover Rules*

The directors of Amgen accept responsibility for the information contained in this report. To the best of the knowledge and belief of the directors (who have taken all reasonable care to ensure that such is the case), the information contained in this report is in accordance with the facts and does not omit anything likely to affect the import of such information.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMGEN INC.

Date: September 11, 2023

By: /s/ Jonathan P. Graham

Name: Jonathan P. Graham

Title: Executive Vice President and General Counsel and Secretary